ABSTRACT
INTRODUCTION
Etest methods provide only inhibitory data and are usually examined at a single time point [58] .
Given this situation, results derived from FIC and Etest methods are not discussed here.
Complicating any discussion of the literature examining antimicrobial combination therapy are the definitions of synergy and antagonism employed. In time-kill studies, synergy has traditionally been defined as a 100-fold increase and antagonism a 100-fold decrease in the observed colony counts at 24 h [58] . Ver. 14 (2015) Unfortunately, the results of these investigations are difficult to interpret due to significant shortcomings in study design and ambiguity in the form of 'colistin' administered (colistin sulfate or CMS). Administration of colistin sulfate is preferable to that of CMS as it permits greater control over the PK profile of the active species, colistin; in patients, colistin forms in vivo following administration of CMS [7, 9, 111, 112] . Importantly, the doses of CMS/colistin employed appear to have been chosen to reflect human doses on a mg/kg basis, ignoring the importance animal scaling that results in dissimilarities across species and likely resulting in substantially lower plasma concentrations in the animals compared with patients [121] . Further complications include the near complete absence of PK data, preventing comparisons with PK profiles achieved in patients, and the small number of isolates tested (many studies utilizing a single isolate). As a result of these significant shortcomings, animal studies are considered only briefly.
Using a reference strain of P. aeruginosa in a mouse pneumoniae model, Aoki et al. [60] observed that all control mice and mice [68] .
As outlined at the beginning of this section, there are significant shortcomings with the existing preclinical in vivo data.
The limited available data do indicate a potential therapeutic benefit for some combinations, particularly colistin plus imipenem or rifampicin against P. aeruginosa, colistin plus piperacillin or doripenem against E. coli, and colistin plus a glycopeptide (but not colistin plus tigecycline) against A.
baumannii. The existing data are limited, however, and firm conclusions cannot be made at this time. Well-designed animal studies which lack the major deficiencies that presently characterize existing investigations are clearly warranted. In particular, future studies should utilize colistin (or polymyxin B) and aim to simulate human PK profiles for each drug, reporting the concentrations achieved. Such studies will be crucial to more accurately assessing the true value of particular combinations and for optimization in patients. Recent studies have suggested the use of a loading dose of 9 million IU per day of CMS (equivalent to *270 mg of CBA) followed by 9 million IU per day in divided doses in order to Qureshi et al. [128] retrospectively examined 41 unique patients with bacteremia caused by KPC-producing K. pneumoniae; of these, 32 (78%) were hospital acquired with the remainder health care associated. Fifteen patients received monotherapy with most receiving CMS or polymyxin B (n = 7), tigecycline (n = 5), or a carbapenem (imipenem or meropenem; n = 4); 15 patients received combination antibiotics.
CLINICAL STUDIES OF CMS OR POLYMYXIN B COMBINATION THERAPY
Unfortunately, the doses of antibiotics administered were not reported. For combination therapy, CMS or polymyxin B were combined with unspecified carbapenems (n = 5), tigecycline (n = 1) or a fluoroquinolone (n = 1) while the most common polymyxin-free combination was tigecycline with either a carbapenem (n = 3) or aminoglycoside (n = 2). The only significant predictor of survival was combination therapy [28-day mortality of 13.3% (2/15) compared to 57.8% (11/19) for monotherapy], with only 1 (14%) of 7 of patients receiving polymyxin combination therapy dying compared to 4 (57.1%) of 7 patients that received polymyxin monotherapy. This latter value is higher than a previous study examining polymyxin B monotherapy against KPC-producing K. pneumoniae [131] and may be due to the greater severity of illness in these mostly critically ill patients. A case-control study conducted in Greece which examined KPC-producing K. pneumoniae bloodstream infections produced similar results [129] . In that study, none of 20 patients receiving multiple antibiotics died (doses not specified; 14 patients received CMS in combination, primarily with tigecycline) compared to 7 (46.7%) of 15 patients receiving monotherapy. Of this latter group, 7 received CMS as monotherapy with 4 (66.7%) dying.
In 23 critically ill patients with a variety of infection types (some with multiple infections) including pneumonia (n = 18), bacteremia (n = 8) and intra-abdominal infections (n = 6) caused by MDR P. aeruginosa, Linden et al. [132] prospectively compared treatment with CMS mono-(n = 10) and combination (n = 13) therapy. CMS was administered IV based on ideal body weight and estimated creatinine clearance (Cr CL *2.7-13.3 mg/kg/day, equivalent to *33,000-167,000 IU/kg/day).
For the combination group, CMS was administered with amikacin or an antipseudomonal b-lactam. An unfavorable response, defined as persistence or worsening of presenting signs and symptoms or death, was reported for 4 (40%) of 10 of patients receiving only CMS and 5 (38.5%) of 13 of patients on combination therapy. In a similar study by Furtado et al. [133] in which polymyxin B (dosed according to Cr CL ; e.g. patients with a
Cr CL C80 mL/min received 1.5-2.5 mg/kg/day) was administered as a continuous infusion over 24 h, polymyxin B combinations [n = 28; most commonly combined with imipenem (n = 24)]
were not found to provide additional benefit over polymyxin B monotherapy (n = 46) for the treatment of nosocomial pneumonia caused by polymyxin-susceptible MDR P. aeruginosa. 
